| |
Patients
|
|---|
|
Characteristics
|
No.
|
%
|
|---|
|
Age, years
| | |
|
Median
|
46
| |
|
Range
|
11-72
| |
|
Sex
| | |
|
Male
|
104
|
75.4
|
|
Female
|
34
|
24.6
|
|
EBV infection
| | |
|
< 1000 copy
|
116
|
84.1
|
|
≥1000 copy
|
22
|
15.9
|
|
Tumor factors
| | |
|
WHO histology
| | |
|
I
|
2
|
1.5
|
|
II
|
99
|
71.7
|
|
III
|
37
|
26.8
|
|
AJCC T category
| | |
|
T1-2
|
100
|
72.5
|
|
T3-4
|
38
|
27.5
|
|
AJCC N category
| | |
|
N0-1
|
78
|
56.5
|
|
N2-3
|
60
|
43.5
|
|
AJCC stage
| | |
|
I
|
6
|
4.4
|
|
II
|
19
|
13.8
|
|
III
|
64
|
46.4
|
|
IVa
|
39
|
28.3
|
|
IVb
|
10
|
7.3
|
|
Treatment factors
| | |
|
IMRT alone
|
25
|
18.1
|
|
IMRT + chemotherapy
|
113
|
81.9
|
|
Chemotherapy manner
| | |
|
Neoadjuvant chemotherapy
|
43
|
31.2
|
|
Concurrent chemotherapy
|
18
|
13.0
|
|
Concurrent +Adjuvant
|
52
|
37.7
|
- WHO = World Health Organization.
- AJCC = American joint committee on carcinoma
- Concurrent +Adjuvant = Concurrent +Adjuvant chemotherapy
